Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/25154
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNg, Sweet Ping-
dc.contributor.authorChu, Julie-
dc.contributor.authorChander, Sarat-
dc.contributor.authorBressel, Mathias-
dc.contributor.authorMcKendrick, Joseph-
dc.contributor.authorWong, Rachel-
dc.contributor.authorSteel, Malcolm-
dc.contributor.authorMurray, William K-
dc.contributor.authorLeong, Trevor-
dc.contributor.authorHeriot, Alexander-
dc.contributor.authorMichael, Michael-
dc.contributor.authorNgan, Samuel Y-
dc.date2020-10-13-
dc.date.accessioned2020-10-27T03:57:23Z-
dc.date.available2020-10-27T03:57:23Z-
dc.date.issued2021-02-
dc.identifier.citationRadiotherapy and Oncology 2021; 155: 27-32en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/25154-
dc.description.abstractThe chemotherapy exposure during chemoradiotherapy for rectal cancer is adequate for radiosensitization but suboptimal for treatment of distant micrometastasis. This study aimed to determine tolerability, dose intensity, response, and toxicity of a novel intensified neoadjuvant treatment approach. Eligible patients were MRI-staged T3-4NxM0 rectal adenocarcinoma. Treatment consisted of FOLFOX chemotherapy given in weeks 1, 6, and 11 with pelvic radiotherapy (25.2Gy in 3 weeks in 1.8Gy/ fraction with oxaliplatin and 5-FU continuous infusion) given in weeks 3-5, and weeks 8-10. Surgery was performed 4 to 6 weeks later. The primary endpoint was tolerability defined as the percentage of patients who were able to complete the planned treatment course. Survival rates were estimated using the Kaplan-Meier method. Median age of the 40 patients was 61.5 years. Rectal MRI-stage was T3 in 88%. Overall, 95% completed the regimen. All patients received 50.4Gy. Relative dose intensity (≥75%) was 92% and 98% for oxaliplatin and 5-FU, respectively. High grade toxicities included neutropenia (25% grade 3; 7.5% grade 4) and diarrhea (10%). Pathologic CR rate was 20%. Median follow-up was 54 months. The 5-year overall survival, freedom from relapse, locoregional control, and freedom from distant metastasis of the cohort was 82%, 72%, 97% and 72%. Delivery of intensified neoadjuvant treatment with interdigitating chemotherapy and radiotherapy is feasible with no increase in acute perioperative complications. A larger prospective study is required to further evaluate the potential survival benefit of this design.en
dc.language.isoeng-
dc.subjectneoadjuvanten
dc.subjectpreoperativeen
dc.subjectradiotherapyen
dc.subjectrectalen
dc.titleResults of Phase II Trial of Intensified Neoadjuvant Treatment with Interdigitating Radiotherapy and Chemotherapy with Oxaliplatin, 5-Fluorouracil and Folinic Acid in Patients with Locally Advanced Rectal Cancer (PROARCT trial).en
dc.typeJournal Articleen
dc.identifier.journaltitleRadiotherapy and Oncologyen
dc.identifier.affiliationDepartment of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne Victoria Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne Victoria Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Eastern Health, Box Hill Hospital, Victoria Australiaen
dc.identifier.affiliationMonash University, Eastern Health Clinical School, Box Hill, Victoria Australiaen
dc.identifier.affiliationDepartment of Surgical Oncology, Peter MacCallum Cancer Centre, Melbourne Victoria Australiaen
dc.identifier.affiliationThe Sir Peter MacCallum Department of Oncology, University of Melbourne..en
dc.identifier.affiliationCentre for Biostatistics and Clinical Trials, Peter MacCallum Cancer Centre, Melbourne Victoria Australiaen
dc.identifier.affiliationRadiation Oncologyen
dc.identifier.affiliationDepartment of Pathology, Peter MacCallum Cancer Centre, Melbourne Victoria Australiaen
dc.identifier.affiliationDepartment of Colorectal Surgery, Box Hill Hospital, Melbourne Victoria Australiaen
dc.identifier.affiliationDepartment of Medical Oncology, Eastern Health, Box Hill Hospital, Victoria Australiaen
dc.identifier.affiliationOlivia Newton-John Cancer Wellness and Research Centreen
dc.identifier.doi10.1016/j.radonc.2020.10.012en
dc.type.contentTexten
dc.identifier.pubmedid33065186-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

32
checked on Jul 1, 2021

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.